BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38016348)

  • 41. Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma.
    Nan H; Guo P; Fan J; Zeng W; Hu C; Zheng C; Pan B; Cao Y; Ge Y; Xue X; Li W; Lin K
    Front Immunol; 2023; 14():1093974. PubMed ID: 36949947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genomic and immunological features of microsatellite instability in colon cancer.
    Luo Y; Yang Z; Chen Y; Lu X; Quan Y
    Gene; 2021 May; 781():145534. PubMed ID: 33636290
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.
    Zhou Y; Yang D; Yang Q; Lv X; Huang W; Zhou Z; Wang Y; Zhang Z; Yuan T; Ding X; Tang L; Zhang J; Yin J; Huang Y; Yu W; Wang Y; Zhou C; Su Y; He A; Sun Y; Shen Z; Qian B; Meng W; Fei J; Yao Y; Pan X; Chen P; Hu H
    Nat Commun; 2020 Dec; 11(1):6322. PubMed ID: 33303760
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification and validation of a seven-gene prognostic marker in colon cancer based on single-cell transcriptome analysis.
    Zhou Y; Guo Y; Wang Y
    IET Syst Biol; 2022 Apr; 16(2):72-83. PubMed ID: 35352485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Copy-number intratumor heterogeneity increases the risk of relapse in chemotherapy-naive stage II colon cancer.
    Lahoz S; Archilla I; Asensio E; Hernández-Illán E; Ferrer Q; López-Prades S; Nadeu F; Del Rey J; Sanz-Pamplona R; Lozano JJ; Castells A; Cuatrecasas M; Camps J
    J Pathol; 2022 May; 257(1):68-81. PubMed ID: 35066875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Using the TCGA Database to Predict and Analyze Tumor Microenvironment Genes Related to Poor Prognosis of Colon Cancer.
    Chen S; Yida L; Chen B; Xiong M
    Med Sci Monit; 2020 Jun; 26():e923707. PubMed ID: 32555128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
    Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
    Front Immunol; 2022; 13():994828. PubMed ID: 36405728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
    Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
    Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration.
    Zhang Y; Zhu B; Cai Y; Zhu S; Zhao H; Ying X; Jiang C; Zeng J
    BMC Cancer; 2022 Jan; 22(1):2. PubMed ID: 34980012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
    Varn FS; Schaafsma E; Wang Y; Cheng C
    Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of prostate cancer subtypes based on immune signature scores in bulk and single-cell transcriptomes.
    Chen C; Luo J; Wang X
    Med Oncol; 2022 Jun; 39(9):123. PubMed ID: 35716212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-cell transcriptome profiling of primary tumors and paired organoids of pancreatobiliary cancer.
    Chen K; Ma Y; Zhong X; Lan J; Long D; Tian X; Yang Y; Yang Y
    Cancer Lett; 2024 Feb; 582():216586. PubMed ID: 38081505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer biology deciphered by single-cell transcriptomic sequencing.
    Li Y; Jin J; Bai F
    Protein Cell; 2022 Mar; 13(3):167-179. PubMed ID: 34405376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
    He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
    Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
    [No Abstract]   [Full Text] [Related]  

  • 56. Colony-stimulating factor 3 signaling in colon and rectal cancers: Immune response and CMS classification in TCGA data.
    Saunders AS; Bender DE; Ray AL; Wu X; Morris KT
    PLoS One; 2021; 16(2):e0247233. PubMed ID: 33606788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
    Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
    Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
    Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.